Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 367

1.

Clinically relevant drug interactions with multikinase inhibitors: a review.

Hussaarts KGAM, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF.

Ther Adv Med Oncol. 2019 Jan 4;11:1758835918818347. doi: 10.1177/1758835918818347. eCollection 2019. Review.

2.

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.

Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P.

Ther Adv Med Oncol. 2019 Jan 2;11:1758835918818351. doi: 10.1177/1758835918818351. eCollection 2019.

3.

Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies.

Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG.

Ther Adv Med Oncol. 2018 Dec 21;10:1758835918816287. doi: 10.1177/1758835918816287. eCollection 2018. Review.

4.

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.

Matutino A, Amaro C, Verma S.

Ther Adv Med Oncol. 2018 Dec 17;10:1758835918818346. doi: 10.1177/1758835918818346. eCollection 2018. Review.

5.

Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.

Young K, Hughes DJ, Cunningham D, Starling N.

Ther Adv Med Oncol. 2018 Dec 17;10:1758835918816281. doi: 10.1177/1758835918816281. eCollection 2018. Review.

6.

Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.

Fabrizio FP, Trombetta D, Rossi A, Sparaneo A, Castellana S, Muscarella LA.

Ther Adv Med Oncol. 2018 Dec 17;10:1758835918815598. doi: 10.1177/1758835918815598. eCollection 2018. Review.

7.

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 Dec 10;10:1758835918815591. doi: 10.1177/1758835918815591. eCollection 2018.

8.

Corrigendum.

[No authors listed]

Ther Adv Med Oncol. 2018 Dec 3;10:1758835918810117. doi: 10.1177/1758835918810117. eCollection 2018.

9.

Corrigendum.

[No authors listed]

Ther Adv Med Oncol. 2018 Dec 3;10:1758835918810116. doi: 10.1177/1758835918810116. eCollection 2018.

10.

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.

Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK.

Ther Adv Med Oncol. 2018 Nov 9;10:1758835918808509. doi: 10.1177/1758835918808509. eCollection 2018. Review.

11.

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).

Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ.

Ther Adv Med Oncol. 2018 Nov 9;10:1758835918807339. doi: 10.1177/1758835918807339. eCollection 2018.

12.

Assessing response to neo-adjuvant therapy in locally advanced rectal cancer using Intra-voxel Incoherent Motion modelling by DWI data and Standardized Index of Shape from DCE-MRI.

Petrillo A, Fusco R, Granata V, Filice S, Sansone M, Rega D, Delrio P, Bianco F, Romano GM, Tatangelo F, Avallone A, Pecori B.

Ther Adv Med Oncol. 2018 Nov 16;10:1758835918809875. doi: 10.1177/1758835918809875. eCollection 2018.

13.

Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.

Battisti NML, De Glas N, Sedrak MS, Loh KP, Liposits G, Soto-Perez-de-Celis E, Krok-Schoen JL, Menjak IB, Ring A.

Ther Adv Med Oncol. 2018 Nov 20;10:1758835918809610. doi: 10.1177/1758835918809610. eCollection 2018. Review.

14.

Durvalumab in NSCLC: latest evidence and clinical potential.

Muñoz-Unceta N, Burgueño I, Jiménez E, Paz-Ares L.

Ther Adv Med Oncol. 2018 Oct 11;10:1758835918804151. doi: 10.1177/1758835918804151. eCollection 2018. Review.

15.

18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature.

Saponara M, Ambrosini V, Nannini M, Gatto L, Astolfi A, Urbini M, Indio V, Fanti S, Pantaleo MA.

Ther Adv Med Oncol. 2018 Aug 30;10:1758835918793569. doi: 10.1177/1758835918793569. eCollection 2018.

16.

Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review.

Dickhoff C, Otten RHJ, Heymans MW, Dahele M.

Ther Adv Med Oncol. 2018 Oct 5;10:1758835918804150. doi: 10.1177/1758835918804150. eCollection 2018. Review.

17.

Primary cilium and glioblastoma.

Álvarez-Satta M, Matheu A.

Ther Adv Med Oncol. 2018 Oct 3;10:1758835918801169. doi: 10.1177/1758835918801169. eCollection 2018. Review.

18.

Corrigendum.

[No authors listed]

Ther Adv Med Oncol. 2018 Sep 24;10:1758835918804576. doi: 10.1177/1758835918804576. eCollection 2018.

19.

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer.

Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, Su WC, Lin CC, Yang SC.

Ther Adv Med Oncol. 2018 Sep 25;10:1758835918797589. doi: 10.1177/1758835918797589. eCollection 2018.

20.

Updates on managing advanced breast cancer with palbociclib combination therapy.

McShane TM, Wolfe TA, Ryan JC.

Ther Adv Med Oncol. 2018 Sep 3;10:1758835918793849. doi: 10.1177/1758835918793849. eCollection 2018. Review. Erratum in: Ther Adv Med Oncol. 2018 Dec 03;10:1758835918810117.

Supplemental Content

Loading ...
Support Center